fatty diacid chain is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-09-07. Numbers and descriptions here follow the published literature rather than marketing material.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
| Property | Value | Notes |
|---|---|---|
| Chemical class | GLP-1 receptor agonist peptide | Mimics endogenous incretin signaling |
| Molecular mass | Approximately 4114 Da | Modified 31-amino-acid backbone |
| Appearance | White to off-white powder | Typical of lyophilized peptide material |
| Solubility | Soluble in water | Behavior depends on salt form and buffer |
| Elimination half-life | About one week | Supported by albumin binding and protease resistance |
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
=== Construction === To expedite the pre-construction work on the expressway, MSRDC decided to divide the design work into 5 packages and hired a separate consultancy firm to prepare the Detailed Project Report (DPR) for each package, On 31 May 2017, the Government of Maharashtra incorporated 'Nagpur Mumbai Super Communication Expressway Limited', a special purpose vehicle (SPV), to manage the financial requirement for the construction and operation of this project. The construction work of the 701 km long Mumbai–Nagpur Expressway is divided into 16 packages, with work awarded to 13 different contractors, including Afcons Infrastructure, Larsen & Toubro (L&T), and Reliance Infrastructure.
She is passionate about music and dresses provocatively; she is also shown to be a gifted pianist. She kissed Adam, but fears for her job after Adam tells Kristina about it. Kristina resolves the situation by telling Rachel never to let it happen again; Rachel agrees. Micah Watson (Hayden Byerly) is Max's best friend in seasons 3 and 4, who uses a wheelchair due to spina bifida. Bob Little (Jonathan Tucker) is a politician who runs for city council in season 3, and for mayor in season 5. Kristina Braverman works on his city council campaign, and runs against him for mayor. In season 3, Bob has a brief fling with Amber, who had been promoted from Kristina's assistant to Bob Little's assistant. Kristina catches them together and thus loses trust in him. Bob Little loses the city council election. Kristina is invited to run Bob Little's mayoral campaign, but decides instead to run against him. Although he runs a smear campaign, Kristina decides not to resort to such tactics. He wins the mayoral election by 2 points (approximately 900 votes). Late in season 5, Kristina is able to get Mayor Bob Little to lease her a building for Chambers Academy, the school she decides to open. Lily (Courtney Ford) is a cellist who records at the Luncheonette in season 3. Crosby, Jabbar, Jasmine, and Dr. Joe attend her performance at the park. Crosby allows Lily to use the extra studio to practice after hours. Lily is Crosby's brief love interest until he and Jasmine reconcile.
== Principle in medical diagnostics == Glycation of proteins is a frequent occurrence, but in the case of hemoglobin, a nonenzymatic condensation reaction occurs between glucose and the N-end of the beta chain. This reaction produces a Schiff base (R−N=CHR', R=beta chain, CHR'=glucose-derived), which is itself converted to 1-deoxyfructose. This second conversion is an example of an Amadori rearrangement. When blood glucose levels are high, glucose molecules attach to the hemoglobin in red blood cells. The longer hyperglycemia occurs in blood, the more glucose binds to hemoglobin in the red blood cells and the higher the glycated hemoglobin. Once a hemoglobin molecule is glycated, it remains that way. A buildup of glycated hemoglobin within the red cell, therefore, reflects the average level of glucose to which the cell has been exposed during its life cycle. Measuring glycated hemoglobin assesses the effectiveness of therapy by monitoring long-term serum glucose regulation. A1c is a weighted average of blood glucose levels during the life of the red blood cells (117 days for men and 106 days in women). Therefore, glucose levels on days nearer to the test contribute substantially more to the level of A1c than the levels on days further from the test. This is also supported by data from clinical practice showing that HbA1c levels improved significantly after 20 days from the start or intensification of glucose-lowering treatment.
Sources: en.wikipedia.org
Sexual dysfunction, including loss of libido, erectile dysfunction, lack of vaginal lubrication, and anorgasmia, are some of the most commonly encountered adverse effects of treatment with fluoxetine and other SSRIs. While early clinical trials suggested a relatively low rate of sexual dysfunction, more recent studies in which the investigator actively inquires about sexual problems suggest that the incidence is >70%. In 2019, the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency recommended that packaging leaflets of selected SSRIs and SNRIs should be amended to include information regarding a possible risk of persistent sexual dysfunction. Following on the European assessment, a safety review by Health Canada "could neither confirm nor rule out a causal link ... which was long lasting in rare cases", but recommended that "healthcare professionals inform patients about the potential risk of long-lasting sexual dysfunction despite discontinuation of treatment".
University-based ophthalmologists in the US and Canada further refined the use of botulinum toxin as a therapeutic agent. By 1985, a scientific protocol of injection sites and dosage had been empirically determined for treatment of blepharospasm and strabismus. Side effects in treatment of this condition were deemed to be rare, mild and treatable. The beneficial effects of the injection lasted only four to six months. Thus, blepharospasm patients required re-injection two or three times a year. In 1986, Scott's micromanufacturer and distributor of Botox was no longer able to supply the drug because of an inability to obtain product liability insurance. People became desperate, as supplies of Botox were gradually consumed, forcing him to abandon people who would have been due for their next injection. For a period of four months, American blepharospasm patients had to arrange to have their injections performed by participating doctors at Canadian eye centers until the liability issues could be resolved. In December 1989, Botox was approved by the US FDA for the treatment of strabismus, blepharospasm, and hemifacial spasm in people over 12 years old. In the case of treatment of infantile esotropia in people younger than 12 years of age, several studies have yielded differing results.
1984: Ong Hwee Kuan, Ong Chin Hock and Yeo Ching Boon were hanged on 24 February 1984 for the robbery, kidnapping and murder of a policeman, Lee Kim Lai, on 25 April 1978. The trio were also responsible for the murder of a taxi driver Chew Theng Hin on the same night Lee was killed. 1986: Sim Min Teck, one of the three perpetrators of the 1980 Jurong fishing port murders, which he committed when he was 18. He was sentenced to death for murder in March 1985 and lost his appeal in July 1986, before he was hanged. 1988: Adrian Lim, Tan Mui Choo, and Hoe Kah Hong, the three perpetrators of the 1981 Toa Payoh ritual murders, were hanged on 25 November 1988. 1988: Sek Kim Wah, a Singaporean military conscript and serial killer who committed the 1983 Andrew Road triple murders and another double murder near Seletar Road, was hanged on 9 December 1988. As of 2024, Sek Kim Wah remains as Singapore's first and only serial killer to date, with 5 victims. 1990: Michael Tan Teow and Lim Beng Hai, the two unemployed Singaporeans and drug abusers who killed a housewife and two children to steal their money to buy drugs. Both were eventually charged with murder, convicted and sentenced to hang. Before his execution however, Tan committed suicide in May 1990, therefore, only Lim was put to death on 5 October 1990. 1992: Hensley Anthony Neville, a Eurasian Singaporean found guilty of the 1984 rape and murder of 19-year-old Lim Hwee Huang. He fled to Malaysia after killing Lim, but was caught in March 1987 and hanged on 28 August 1992 after a six-day trial hearing.
Arizona Medical Training Institute (AMTI) is a private, vocational healthcare institute located in Mesa, Arizona. They provide entry-level medical training for students seeking careers in nursing, clinical laboratory science and the assisted living career fields.
Sources: en.wikipedia.org
1,2-Diarylethylamines exert their primary effects as uncompetitive antagonists of the N-methyl-D-aspartate receptor (NMDAR), similar to phencyclidine (PCP) and ketamine. This mechanism is believed to underlie their characteristic dissociative, hallucinogenic, and anesthetic properties. Compounds such as diphenidine, methoxphenidine (MXP), and ephenidine display high to moderate affinity for the NMDAR PCP-binding site (e.g., diphenidine Ki ≈ 18–39 nM). Additionally, some members of this class exhibit secondary interactions with monoamine transporters, including the dopamine and norepinephrine transporters (DAT and NET), as well as modest binding to sigma-1 and sigma-2 receptors, serotonin 5-HT2A receptors, alpha-adrenergic receptors, and the kappa opioid receptor. Despite potent NMDAR binding, several compounds exhibit reduced in vivo potency, potentially due to pharmacokinetic factors.
=== CT and MRI scans === Imaging of the pituitary gland is important in confirming hypersomatotropism in cats where it is suspected. Showing a pituitary mass is important to establish a final diagnosis alongside clinical findings and hormonal findings. Knowing the size of the pituitary mass is also necessary to decide the best course of treatment. In the vast majority of cats with hypersomatropism, it is caused by an adenoma of the somatotrophic cells. Said adenoma is typically visible by the time a cat presents with symptoms; however, if pituitary imaging is performed during the early stages of the disease, it may still be small and difficult to recognise. Rarely CT/MRI imaging may not reveal anything, this may either due to a small size of the tumour or due to a different aetiology for the acromegaly. Rarely in humans with acromegaly, somatotrophic hyperplasia as the result of growth hormone releasing hormones, caused by a tumour. This aetiology has not been observed in cats; however, a cat with normal CT and MRI imaging, the histopathology showed—instead of adenoma—acidophilic proliferation.
== Signs and symptoms == The hallmark of polymyositis is weakness and/or loss of muscle mass in the proximal musculature, as well as flexion of the neck and torso. These symptoms can be associated with marked pain in these areas as well. The hip extensors are often severely affected, leading to particular difficulty in climbing stairs and rising from a seated position. The skin involvement of dermatomyositis is absent in polymyositis. Dysphagia (difficulty swallowing) or other problems with esophageal motility occur in as many as 1/3 of patients. Low grade fever and enlarged lymph nodes may be present. Foot drop in one or both feet can be a symptom of advanced polymyositis and inclusion body myositis. The systemic involvement of polymyositis includes interstitial lung disease (ILD) and heart disease, such as heart failure and conduction abnormalities. Polymyositis tends to become evident in adulthood, presenting with bilateral proximal muscle weakness often noted in the upper legs due to early fatigue while walking. Sometimes the weakness presents itself as an inability to rise from a seated position without help or an inability to raise one's arms above one's head. The weakness is generally progressive, accompanied by lymphocytic inflammation (mainly cytotoxic T cells).
=== Depression === A 2016 Cochrane review concluded that for major depressive disorder, "Given the absence of high quality evidence and the inability to draw firm conclusions based on that evidence, the use of SAMe for the treatment of depression in adults should be investigated further.". A 2020 systematic review found that it performed significantly better than placebo, and had similar outcomes to other commonly used antidepressants (imipramine and escitalopram).
However, though the Huks fought the Japanese, they also "tried to thwart United States Army Forces in the Far East guerrillas", "therefore, they were considered disloyal and were not accorded U.S. recognition or benefits at the end of the war."
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and cleared quickly. Semaglutide carries a position 8 substitution that blocks that cleavage and a fatty diacid chain that binds albumin. Together these changes extend its circulating half-life to about one week.
Yes. Stimulation of insulin secretion is glucose-dependent, meaning the effect is larger when blood glucose is high and minimal when it is normal. This property separates GLP-1 receptor agonists from agents that drive insulin release regardless of glucose level.
Receptor expression in hypothalamic and brainstem regions is well documented, and reduced energy intake is consistently observed. The relative contribution of central versus peripheral signaling to total weight change is still an open question addressed by ongoing research.
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.